In CKD-MBD management, which strategy is used to prevent vascular calcifications and maintain bone health?

• A. Use calcium-based phosphate binders exclusively
• B. Use non-calcium-based phosphate binders, appropriate vitamin D analogs, and calcimimetics
• C. Avoid any phosphate binders
• D. Use high-dose calcium supplementation

Answer: (C)

In CKD-MBD, the goal is to keep phosphate under control, avoid excess calcium loading, and suppress secondary hyperparathyroidism to protect both bone health and the vasculature. The best strategy combines non-calcium–based phosphate binders to lower phosphate without raising calcium levels, with appropriate vitamin D analogs to help control PTH, and calcimimetics to reduce PTH further without increasing calcium or phosphate. This approach lowers the calcium-phosphate product and reduces the risk of vascular calcifications, while supporting healthier bone turnover.

Using calcium-based phosphate binders alone would raise calcium intake and can promote vascular calcification. Skipping phosphate binders altogether allows phosphate to rise, worsening bone and vascular issues. High-dose calcium supplementation similarly increases calcium load and can contribute to vascular calcifications.